Question
To ask Her Majesty’s Government whether there are any licensed centres for which the incidence of ovarian hyperstimulation syndrome is equal to or greater than that described in 2007 in the journal Human Fertility (volume 10, issue 3, pages 183–187); and which centres were responsible for generating the data described in this paper.
Answer
The prescribing of fertility drugs that can lead to ovarian hyper-stimulation syndrome (OHSS) is not a licensable activity under the Human Fertilisation and Embryology Act 1990 and is therefore not regulated by the Human Fertilisation and Embryology Authority (HFEA). The HFEA does not routinely collect information about cases of OHSS occurring in connection with treatment at each HFEA licensed centre, other than where this is reported in the context of an adverse incident report. While the HFEA receives limited data about OHSS it is not possible from these data to calculate the incidence of OHSS for each clinic in relation to the population treated. The HFEA has advised that it cannot comment on centres that were responsible for generating the data in the paper referred to in Human Fertility (volume 10, issue 3, pages 183 — 187). The HFEA did not write or contribute data to the paper.